Neoadjuvant Cancer Immunotherapy Set For Takeoff, Fueled By Strong Data

Dreams of a future with early curative treatments drives wave of drug development in pre-surgical and perioperative treatment in many tumor types.

Neoadjuvant use of IO therapy is set for launch

Neoadjuvant cancer immunotherapy is poised to advance in 2025 and beyond, giving hope that in the future patients could be cured early, perhaps escaping debilitating surgeries. For biopharma companies, the race is on to efficiently detect early signals of efficacy and develop safe and effective regimens suitable for pre-surgical use.

More from Outlook

Outlook 2025: Will Geopolitics Dampen Pharma’s Comeback Party?

 
• By 

The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.

Biopharma Plumps Pipeline With Healthy Weight Loss Candidates

 
• By 

Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.

Benzos to Breakthroughs: Bill Burns on Roche's Transformation

 
• By 

Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.

Medtech Industry Reaches New Chapter In Its Structural Evolution

 
• By 

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

More from Innovation

BPGbio: Fusing Patient-Driven Innovation With Causal AI

 
• By 

Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.

20 Voices: What Does 2025 Hold For Biopharma?

 

Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

 
• By 

Neutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.